ARCHIVES

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

October 31, 2014

DCBDC Board Cool to Proposals On Study Sections

November 23, 1990

Cancer Groups Criticize FDA For Ignoring Expert Advice.

November 24, 2000

In Brief: Interim Dean Henney Looking for Cancer Center Director; Shingleton Gets James Ewing Award

June 10, 1988

Congress Approves More Favorable Terms for Office-Administered Drugs

August 8, 1997

Berlin, DeVita Differ On Use Of L-PAM

November 8, 1974